|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||8.91 - 9.02|
|52 Week Range||2.67 - 9.68|
|PE Ratio (TTM)||212.38|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||4.00|
COLUMBIA, Md., Feb. 06, 2018-- Osiris Therapeutics, Inc. is pleased to announce that its Board of Directors, at a Board Meeting on February 6 th, 2018, appointed Mr. Willi Miesch as a Director, upon recommendation ...
SAN DIEGO, CA / ACCESSWIRE / November 28, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors who purchased NASDAQ: OSIR shares against Osiris Therapeutics, ...
A former chief financial officer of biotechnology company Osiris Therapeutics on Thursday pleaded guilty to making false statements to auditors to inflate the company's reported revenue. Philip Jacoby, 65, entered his plea before U.S. District Judge Denise Cote in in Manhattan, while Osiris separately agreed to pay $1.5 million to settle a related civil lawsuit by the U.S. Securities and Exchange Commission, court records showed. As part of the plea, Jacoby and prosecutors agreed that an appropriate sentence under federal guidelines would be four to 10 months in prison and a fine of up to $5 million.
NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Stocks of both companies rose on future-oriented news for investors. While FDA clinical trials continue, both companies are getting positive news coverage from ...
NEW YORK, NY / ACCESSWIRE / March 14, 2017 / The competition between Osiris Therapeutics and competitor PTC has ended with an unceremonious thud. Osiris has come to the end of its NASDAQ run today, after ...